Viscosupplementation Market - Size & Upcoming Industry Trends 2024-2032

Viscosupplementation Market Synopsis:

Viscosupplementation Market Size Was Valued at USD 4.83 Billion in 2023, and is Projected to Reach USD 11.09 Billion by 2032, Growing at a CAGR of 9.58% From 2024-2032.

Hyaluronic acid injection is a non-surgical management technique of osteoarthritis, where hyaluronic acid is injected into joint spaces, of which the knee joint is most common. HA is a natural material found in synovial fluid that involves independent action as a lubricant and as a shock absorber; however, it is usually degraded in osteoarthritis patients. The injected HA replaces this loss and helps to regain functionality while decreasing pain. Arthritis health management takes various forms with one of the latest common methods being viscosupplementation, especially for patients who have not been relieved by use of drugs for the management of pain or those who have not benefited from physical therapy, but cannot yet undergo joint replacement surgery.

There has been steady growth in the viscosupplementation market mainly due to the increasing incidence of osteoarthritis especially among patients of a growing age globally. As life, spans extended, so has the prevalence of osteoarthritis, hence increasing the need for safer and efficient interventional methods such as viscosupplementation. This demand is further driven by what we find is more people rising up with joint pain issues due to activities, obesity and other health complications. Current osteoarthritis management includes viscosupplementation as a safe and effective method of treatment with an increasing range of HA products available: the variety of products are differentiated based on duration of effectiveness and the interval between the injections.

Technological developments and high investment in HA formulations are furthermore influencing the viscosupplementation market. Leading manufacturers are looking for methods to improve the properties of HA therefore making it more durable, and effective for patients who would require less frequent injections. Market expansion is also occurring due to improvements in health care industry in developing nations, in terms of knowledge of being an option to viscosupplementation from both the providers’ and the patients’ side. He said that with increase in the extent of utilization of these products by healthcare professionals, the growth of the viscosupplementation market will be sustained.

Viscosupplementation Market Trend Analysis:

Innovation in Extended-Release Hyaluronic Acid Formulations

• An interesting trend being witnessed in the global market for viscosupplementation is the future formulations of the product with longevity than Octenyl Very similar to the Geliflex_(R) ORIGINAL HYAL GEL version, it is high time that more product formulation of viscosupplementation is produced with longer period of usage in the Osteoarthritis painful symptoms. HA injections of the conventional methods could be invasive and may need to be reinforced many times within a short period, which might be an inconvenience to the patients, and may be costly. To facilitate this issue, the leading companies are approaching the issue of the research and development of formulations that can increase the time during which HA stays in the joint space. The new products present a chance of getting longer effects and therefore urging doctors as well as patients to opt for viscosupplementation.
• Besides, these extended-release formulations are considered as one of the strategies that can be used to facilitate product differentiation in a highly saturated market so that organizations can gain advantage. Patients are moving up the0033 ladder looking for not only solutions that are effective but also convenient, and longer lasting HA formulations would therefore have the potential of needing less treatments per year. Such florid will most probably continue as organizations try to improve patient satisfaction and push for more market shares with novelties.

Expansion in Emerging Markets

• The key trends constituting the viscosupplementation market are: high growth opportunity in the up-and-coming economies linked with the development in the healthcare industry and significant patient awareness about OA treatment. We anticipate increased interest in viscosupplementation and other comparable non-surgical treatments for pain in these regions because with the increasing availability of health care to every person, more people in these places will require treatment for joint pains in the future. In addition, there is also the demographical factor which denotes that aging is gradually becoming rampant in many emergent markets globally similar to the developed world and this place the emergent markets on the route map to escalating incidences of osteoarthritis.

Viscosupplementation Market Segment Analysis:

Viscosupplementation Market Segmented on the basis of Product, Application, End User, and Region.

By Type, Single Injection segment is expected to dominate the market during the forecast period

• Single Injection segment is anticipated to contribute the largest share to the viscosupplementation market during the forecast period. Compared to multi-injection regimens, single injection has its advantages, as the process is longer, and the effect is achieved much faster, which is good both for the patients and the healthcare providers. This kind minimises the number of patients’ outpatient attendances and the costs related thereto while enhancing the satisfaction of the patient. Due to change in technologies in the hyaluronic acid preparation, single injection categories are gaining popularity in delivering lasting results which makes them more attractive. Therefore, the single-injection segment is expected to drive market growth as it aligns with healthcare infrastructure demands and adjunct minimally invasive treatment procedures requirements in developed countries, demanding markets with high consumer need.

By Application, Knee segment expected to held the largest share

• The key Segment which is the Knee segment is expected to dominate the viscosupplementation market due to heightened incidences of knee osteoarthritis as a result of increased life span and active life styles. The knee joint is exposed to mechanical stress and as a result of this, the osteoarthritis condition affects this area causing immense pressure of demand of better pain management and joint mobility. Of the various forms of OA, knee OA stands to benefit most from viscosupplementation since surgical intervention such as knee replacement surgery becomes inevitable in the later stages of the disease. Due to developments in hyaluronic acid formulations that can be used for knee treatments in particular, users and clinicians keep interesting in this segment, thus this segment remains to be on the leading position in the market.

Viscosupplementation Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America remains the largest region in the context of the global viscosupplementation market in 2023 because there are many people with osteoarthritis in this area, and the developed healthcare system provides the best opportunities for utilizing complex methods of treatment. The largest consumer is the United States, which purchases about 40 percent of all invasive species globally. This dominance is explained by the increasing demand for pain management, the availability of reimbursement policies for elderly patients and the presence of high quality Viscosupplements on the market. Canada is also involved with rising trends attributed to patients’ knowledge and healthcare processes.

Active Key Players in the Viscosupplementation Market:

• Anika Therapeutics (USA)
• Bioventus (USA)
• Chugai Pharma (Japan)
• Ferring Pharmaceuticals (Switzerland)
• Fidia Farmaceutici (Italy)
• Hyaltech Ltd (UK)
• LG Life Sciences (South Korea)
• Regen Lab SA (Switzerland)
• Sanofi (France)
• Seikagaku Corporation (Japan)
• Shanghai Jingfeng Pharmaceutical (China)
• Smith & Nephew (UK)
• TRB Chemedica International (Switzerland)
• Virchow Biotech (India)
• Zimmer Biomet (USA)
• Other Active Players